SARS-CoV-2 protein NSP5

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (13:49, 14 February 2022) (edit) (undo)
 
(3 intermediate revisions not shown.)
Line 1: Line 1:
== Main Protease ==
== Main Protease ==
<SX viewer='molstar' load='6y2e' size='350' side='right' caption='Main protease from SARS-CoV2 (PDB entry [[6y2e]])' scene=''>
<SX viewer='molstar' load='6y2e' size='350' side='right' caption='Main protease from SARS-CoV2 (PDB entry [[6y2e]])' scene=''>
-
SARS-CoV-2 is a positive-stranded RNA virus with nucleocapsid which belongs to betacoronaviruses. The 30 kb long +ssRNA contains a 5’-cap structure and a 3’-poly-A tail. After membrane fusion, the viral +ssRNA is released into the cytoplasm and translated into two polyproteins pp1a and pp1ab<ref> Guo, Y.-R., Cao, Q.-D., Hong, Z.-S., Tan, Y.-Y., Chen, S.-D., Jin, H.-J., Tan, K.-S., Wang, D.-Y. & Yan, Y. (2020). Mil Med Res. 7. </ref> <ref> Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C. & Di Napoli, R. (2020). StatPearls, Vol. p. Treasure Island (FL): StatPearls Publishing </ref>. NSP3, a Papain-like protease(s) and '''nsp5''', the main protease (also called 3C-like protease [[3CLpro]]) are essential for processing the two polyproteins pp1a and pp1ab.
+
SARS-CoV-2 is a positive-stranded RNA virus with nucleocapsid which belongs to betacoronaviruses. The 30 kb long +ssRNA contains a 5’-cap structure and a 3’-poly-A tail. After membrane fusion, the viral +ssRNA is released into the cytoplasm and translated into two polyproteins pp1a and pp1ab<ref> Guo, Y.-R., Cao, Q.-D., Hong, Z.-S., Tan, Y.-Y., Chen, S.-D., Jin, H.-J., Tan, K.-S., Wang, D.-Y. & Yan, Y. (2020). Mil Med Res. 7. </ref> <ref> Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C. & Di Napoli, R. (2020). StatPearls, Vol. p. Treasure Island (FL): StatPearls Publishing </ref>. NSP3, a Papain-like protease(s) and '''NSP5''', the main protease (also called 3C-like protease [[3CLpro]]) are essential for processing the two polyproteins pp1a and pp1ab.
The coronavirus ORF 1 polyprotein can be divided into an N-terminal region that is processed by one or two Papain-like proteases and a C-terminal region which is processed by the main protease<ref> Enjuanes, L., (2005). Coronavirus replication and reverse genetics Berlin; New York: Springer, S. 69-78. </ref>. While papain-like protease(s) cleave only three sites, the main protease cleaves 11 sites in the polyprotein to generate functional proteins. Additionally, the main protease cleaves its own N- and C-terminal autoprocessing sites. The cleaved functional proteins include viral enzymes needed for replication such as the RNA-dependant RNA polymerase, a helicase and other non-structural or accessory proteins such as an exoribonuclease, an endoribonuclease, a ssRNA binding protein and a 2’-O-ribose methyltransferase<ref> Muramatsu, T., Takemoto, C., Kim, Y.-T., Wang, H., Nishii, W., Terada, T., Shirouzu, M. & Yokoyama, S. (2016). Proc Natl Acad Sci U S A. 113, 12997–13002. </ref>.
The coronavirus ORF 1 polyprotein can be divided into an N-terminal region that is processed by one or two Papain-like proteases and a C-terminal region which is processed by the main protease<ref> Enjuanes, L., (2005). Coronavirus replication and reverse genetics Berlin; New York: Springer, S. 69-78. </ref>. While papain-like protease(s) cleave only three sites, the main protease cleaves 11 sites in the polyprotein to generate functional proteins. Additionally, the main protease cleaves its own N- and C-terminal autoprocessing sites. The cleaved functional proteins include viral enzymes needed for replication such as the RNA-dependant RNA polymerase, a helicase and other non-structural or accessory proteins such as an exoribonuclease, an endoribonuclease, a ssRNA binding protein and a 2’-O-ribose methyltransferase<ref> Muramatsu, T., Takemoto, C., Kim, Y.-T., Wang, H., Nishii, W., Terada, T., Shirouzu, M. & Yokoyama, S. (2016). Proc Natl Acad Sci U S A. 113, 12997–13002. </ref>.
Line 11: Line 11:
== 3CLpro as Potential Drug Target ==
== 3CLpro as Potential Drug Target ==
-
Due to a new outbreak of pulmonary diseases caused by SARS-CoVid-2, the development of new drugs is essential for containment of the viral spread. One promising drug target among coronaviruses is the main protease, as it is essential for processing the polyproteins translated from the viral RNA. Inhibiting this enzyme would block the viral replication and is unlikely to be toxic, as no human proteases with similar cleavage specificity are known. <ref> Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K. & Hilgenfeld, R. (2020). Science. </ref> The potential inhibitor classes can be divided into two classes based on their chemical structures. The first class involves peptide chains that fit the catalytic site of the enzyme by making a covalent link with Cys145, therefore blocking substrate binding. The second class consists of small organic compounds that bind the active site and hence act as competitive inhibitors. Thus, the substrate can not enter the active site cavity. A potential drug which belongs to the second class is Lopinavir, a HIV1 protease inhibitor which seems to be a promising candidate for the treatment of coronavirus infections. <ref> Dayer, M. R., Taleb-Gassabi, S. & Dayer, M. S. (2017). Lopinavir; A Potent Drug against Coronavirus Infection: Insight from Molecular Docking Study. </ref>
+
Due to a new outbreak of pulmonary diseases caused by SARS-CoVid-2, the development of new drugs is essential for containment of the viral spread. One promising drug target among coronaviruses is the main protease, as it is essential for processing the polyproteins translated from the viral RNA. Inhibiting this enzyme would block the viral replication and is unlikely to be toxic, as no human proteases with similar cleavage specificity are known. <ref>PMID: 32198291</ref><ref>PMID: 32272481</ref>The potential inhibitor classes can be divided into two classes based on their chemical structures. The first class involves peptide chains that fit the catalytic site of the enzyme by making a covalent link with Cys145, therefore blocking substrate binding. The second class consists of small organic compounds that bind the active site and hence act as competitive inhibitors. Thus, the substrate can not enter the active site cavity. A potential drug which belongs to the second class is Lopinavir, a HIV1 protease inhibitor which seems to be a promising candidate for the treatment of coronavirus infections. <ref> Dayer, M. R., Taleb-Gassabi, S. & Dayer, M. S. (2017). Lopinavir; A Potent Drug against Coronavirus Infection: Insight from Molecular Docking Study. </ref>
</SX>
</SX>
 +
 +
==See also==
 +
 +
[[Coronavirus_Disease 2019 (COVID-19)]]<br>
 +
[[SARS-CoV-2_virus_proteins]]<br>
 +
[[COVID-19 AlphaFold2 Models]]
== References ==
== References ==
<references/>
<references/>

Current revision

Main Protease

Main protease from SARS-CoV2 (PDB entry 6y2e)

See also

Coronavirus_Disease 2019 (COVID-19)
SARS-CoV-2_virus_proteins
COVID-19 AlphaFold2 Models

References

  1. Guo, Y.-R., Cao, Q.-D., Hong, Z.-S., Tan, Y.-Y., Chen, S.-D., Jin, H.-J., Tan, K.-S., Wang, D.-Y. & Yan, Y. (2020). Mil Med Res. 7.
  2. Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C. & Di Napoli, R. (2020). StatPearls, Vol. p. Treasure Island (FL): StatPearls Publishing
  3. Enjuanes, L., (2005). Coronavirus replication and reverse genetics Berlin; New York: Springer, S. 69-78.
  4. Muramatsu, T., Takemoto, C., Kim, Y.-T., Wang, H., Nishii, W., Terada, T., Shirouzu, M. & Yokoyama, S. (2016). Proc Natl Acad Sci U S A. 113, 12997–13002.
  5. Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L., Mo, L., Ye, S., Pang, H., Gao, G. F., Anand, K., Bartlam, M., Hilgenfeld, R. & Rao, Z. (2003). Proc Natl Acad Sci U S A. 100, 13190–13195.
  6. Xu, T., Ooi, A., Lee, H. C., Wilmouth, R., Liu, D. X. & Lescar, J. (2005). Acta Crystallogr Sect F Struct Biol Cryst Commun. 61, 964–966.
  7. Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R. & Hilgenfeld, R. (2003). Science. 300, 1763–1767.
  8. Yang, H., Xie, W., Xue, X., Yang, K., Ma, J., Liang, W., Zhao, Q., Zhou, Z., Pei, D., Ziebuhr, J., Hilgenfeld, R., Yuen, K. Y., Wong, L., Gao, G., Chen, S., Chen, Z., Ma, D., Bartlam, M. & Rao, Z. (2005). PLoS Biol. 3.
  9. Gorbalenya, A. E., Snijder, E. J. & Ziebuhr, J. (2000). Journal of General Virology. 81, 853–879.
  10. Xue, X., Yu, H., Yang, H., Xue, F., Wu, Z., Shen, W., Li, J., Zhou, Z., Ding, Y., Zhao, Q., Zhang, X. C., Liao, M., Bartlam, M. & Rao, Z. (2008). Journal of Virology. 82, 2515–2527.
  11. Rut, W., Groborz, K., Zhang, L., Sun, X., Zmudzinski, M., Hilgenfeld, R. & Drag, M. (2020). BioRxiv. 2020.03.07.981928.
  12. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science. 2020 Mar 20. pii: science.abb3405. doi: 10.1126/science.abb3405. PMID:32198291 doi:http://dx.doi.org/10.1126/science.abb3405
  13. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, Duan Y, Yu J, Wang L, Yang K, Liu F, Jiang R, Yang X, You T, Liu X, Yang X, Bai F, Liu H, Liu X, Guddat LW, Xu W, Xiao G, Qin C, Shi Z, Jiang H, Rao Z, Yang H. Structure of M(pro) from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9. pii: 10.1038/s41586-020-2223-y. doi:, 10.1038/s41586-020-2223-y. PMID:32272481 doi:http://dx.doi.org/10.1038/s41586-020-2223-y
  14. Dayer, M. R., Taleb-Gassabi, S. & Dayer, M. S. (2017). Lopinavir; A Potent Drug against Coronavirus Infection: Insight from Molecular Docking Study.

Proteopedia Page Contributors and Editors (what is this?)

Joel L. Sussman

Personal tools